ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other Events
Item 8.01 Other Events
On January 15, 2019, ContraVir Pharmaceuticals,Inc. (the “Company”) announced that its 2018 Annual Meeting of Stockholders scheduled to be held on January15, 2019 (the “Annual Meeting”) was adjourned due to a lack of a quorum on the proposals to be approved. The Company intends to set a new record date and will add additional proposals to be voted on at the Annual Meeting. The press release is attached as Exhibit99.1 to this report on Form8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
|
99.1 |
ContraVir Pharmaceuticals,Inc. Press Release dated January15, 2019 |
ContraVir Pharmaceuticals, Inc. Exhibit
EX-99.1 2 a19-2959_1ex99d1.htm EX-99.1 Exhibit 99.1 ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders EDISON,…
To view the full exhibit click here
About ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV)
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.